TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
1-Year Return
35.44%
This Quarter Return
+25.92%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$269M
AUM Growth
-$59.6M
(-18%)
Cap. Flow
-$73.8M
Cap. Flow
% of AUM
-27.47%
Top 10 Holdings %
Top 10 Hldgs %
55.73%
Holding
84
New
36
Increased
10
Reduced
12
Closed
25
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$21.1M |
| 2 |
Medtronic
MDT
|
$14.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$8.66M |
| 4 |
Legend Biotech
LEGN
|
$8.06M |
| 5 |
DexCom
DXCM
|
$6.66M |
Top Sells
| 1 |
Abbott
ABT
|
$17.7M |
| 2 |
Tandem Diabetes Care
TNDM
|
$17M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$16.3M |
| 4 |
ARK Innovation ETF
ARKK
|
$14.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
$12.3M |
Sector Composition
| 1 | Healthcare | 99.2% |
| 2 | Financials | 0.24% |
| 3 | Industrials | 0.21% |
| 4 | Energy | 0.12% |
| 5 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Editas Medicine
EDIT
$227M
| $3.05M | 1.13% |
+370,877
| New | +$3.05M |
|
27
Merus
MRUS
$5.01B
| $2.68M | 1% |
+101,691
| New | +$2.68M |
|
28
Natera
NTRA
$22.9B
| $2.58M | 0.96% |
+52,964
| New | +$2.58M |
|
29
Roivant Sciences
ROIV
$8.58B
| $2.04M | 0.76% |
202,406
-142,124
| -41% | -$1.43M |
|
30
Ventyx Biosciences
VTYX
$185M
| $1.9M | 0.7% |
57,800
-95,042
| -62% | -$3.12M |
|
31
Astria Therapeutics
ATXS
$395M
| $1.87M | 0.69% |
224,074
-50,937
| -19% | -$424K |
|
32
Vera Therapeutics
VERA
$1.4B
| $1.75M | 0.65% |
+108,928
| New | +$1.75M |
|
33
Mersana Therapeutics
MRSN
$35.5M
| $1.41M | 0.52% |
+17,132
| New | +$1.41M |
|
|
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.31M | 0.49% |
+41,292
| New | +$1.31M |
|
35
PMV Pharmaceuticals
PMVP
$76.3M
| $992K | 0.37% |
+158,413
| New | +$992K |
|
36
Immatics
IMTX
$695M
| $947K | 0.35% |
+82,052
| New | +$947K |
|
37
Xenon Pharmaceuticals
XENE
$2.98B
| $933K | 0.35% |
24,221
-197,509
| -89% | -$7.6M |
|
38
Protagonist Therapeutics
PTGX
$3.71B
| $932K | 0.35% |
33,750
-99,702
| -75% | -$2.75M |
|
|
MRTX
39
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $874K | 0.33% |
+24,201
| New | +$874K |
|
40
Schrodinger
SDGR
$1.4B
| $822K | 0.31% |
+16,462
| New | +$822K |
|
41
Cogent Biosciences
COGT
$1.81B
| $792K | 0.29% |
+66,885
| New | +$792K |
|
|
CBAY
42
DELISTED
Cymabay Therapeutics
CBAY
| $773K | 0.29% |
+70,588
| New | +$773K |
|
43
Aldeyra Therapeutics
ALDX
$332M
| $613K | 0.23% |
+73,067
| New | +$613K |
|
|
INBX
44
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $396K | 0.15% |
+15,268
| New | +$396K |
|
45
Amphenol
APH
$138B
| $223K | 0.08% |
+5,258
| New | +$223K |
|
46
Dover
DOV
$24.5B
| $223K | 0.08% |
+1,512
| New | +$223K |
|
47
Hartford Financial Services
HIG
$37.9B
| $219K | 0.08% |
+3,034
| New | +$219K |
|
48
Prudential Financial
PRU
$38.3B
| $217K | 0.08% |
+2,463
| New | +$217K |
|
49
Colgate-Palmolive
CL
$67.6B
| $208K | 0.08% |
+2,701
| New | +$208K |
|
50
Cintas
CTAS
$83.4B
| $206K | 0.08% |
+1,656
| New | +$206K |
|